A Phase I Study of the Combination of Radiation Therapy (RT), Arsenic Trioxide (ATO) and Temozolomide (TMZ) in Patients With Newly-Diagnosed Glioblastoma Multiforme (GBM).

Trial Profile

A Phase I Study of the Combination of Radiation Therapy (RT), Arsenic Trioxide (ATO) and Temozolomide (TMZ) in Patients With Newly-Diagnosed Glioblastoma Multiforme (GBM).

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs Arsenic trioxide (Primary) ; Temozolomide
  • Indications Anaplastic astrocytoma; Glioblastoma; Gliosarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Jul 2016 Last checked against clinicaltrials.gov record.
    • 10 Aug 2010 Actual end date (February 2009) added as reported by ClinicalTrials.gov.
    • 10 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top